The Biotech Social Pact gathers CEOs and leaders of biotech and life sciences who are committed to working alongside high-level policymakers and health authorities to sustainably grow the biotech ecosystem whilst ensuring timely and widespread access to innovative treatments for patients and health systems across Europe. The Biotech Social Pact does not necessarily reflect the policies or positions of the agencies, organizations, employers, or companies with which the signatories are affiliated. United in upholding common principles and beliefs, our members are diverse assembly of leading organisations that are often not represented in trade associations, including pre- and early commercial companies, venture capital firms and individual industry leaders. The BSP is not a trade association and coexists alongside existing biopharma trade associations. It aims at offering a supporting voice to emerging and rapidly growing global biotech companies and to contribute to awareness of biotech and support the biotech ecosystem at large. The Biotech Social Pact is managed by Portland, a global Public Affairs company, with the financial support of Alnylam Pharmaceuticals, Amicus, argenx and Ultragenyx.